Pubmed- Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment - IBD Reporter Newsfeed - IBD Support Group Forums -


Jump to content

- - - - -

Pubmed- Polyvinyl Butyrate Nanoparticles as Butyrate Donors for Colitis Treatment

  • Please log in to reply
No replies to this topic

#1 Health Reporter

Health Reporter


  • RSS
  • PipPipPipPip
  • 20943 posts
  • Country:United States

Posted 11 January 2022 - 06:19 PM


ACS Appl Bio Mater. 2021 Mar 15;4(3):2335-2341. doi: 10.1021/acsabm.0c01105. Epub 2021 Feb 11.


Butyrate has been attracting attention for the suppression of inflammatory bowel disease (IBD). However, clinical trials of butyrate for IBD treatment have resulted in controversial outcomes, likely owing to the adverse effect of butyrate on the intestinal epithelium that was observed at high butyrate concentrations. Herein, we propose polyvinyl butyrate (PVBu) nanoparticles (NPs) as butyrate donors for delivery to the lower part of the intestine for the treatment of colitis. The PVBu NPs suppressed the inflammatory activation of macrophages in vitro, although sodium butyrate inversely further activated macrophages. Oral administration of NPs did not change the luminal concentration of free butyrate; however, NPs showed a therapeutic effect on a colitis mouse model. In addition, incorporation of vitamin D3 into the NPs enhanced the therapeutic effect on colitis. Hence, PVBu NPs are a promising therapeutic for IBD treatment, not only as a butyrate donor but also as a carrier for hydrophobic drugs like vitamin D3.

PMID:35014354 | DOI:10.1021/acsabm.0c01105

View the full article


© Copyright 1995-2014 IBD Support All rights reserved.

About Us | Contact Us | Advertise With Us | Disclaimer | Terms of Service | Crisis Resources

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here